prohibited substance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
VP-13 operating PB2Y-3s from 26 February to 22 June 1944 VP-16 operating PBM-3Ds from 7 June to 1 August 1944 VP-21 operating PBM-3Ds from 19 August to 17 October 1944 and from 15 July to 11 September 1945 VP-23 operating PBY-5As from 20 August 1944 to 9 April 1945 VP-MS-6 operating PBM-5Es from 1 February 1948 in support of Operation Sandstone VP-102 operating PB2Y-3s from 3 February to 30 August 1944 VP-202 operating PBM-3Ds from 24 February to 1 March 1944 VPB-19 operating PBM-3Ds from 2 November 1944 to 12 February 1945 and 6 March 1945 to January 1946 VPB-22 operating PBM-3Ds from 10 October to 30 November 1944 and from 25 June to 7 August 1945
Births from January–October 2016 = 62,761 Births from January–October 2017 = 61,314 Deaths from January–October 2016 = 75,733 Deaths from January–October 2017 = 75,804 Natural growth from January–October 2016 = -12,972 Natural growth from January–October 2017 = -14,490
Strategies for preventing link rot can focus on placing content where its likelihood of persisting is higher, authoring links that are less likely to be broken, taking steps to preserve existing links, or repairing links whose targets have been relocated or removed.
These clay lenses can slow or stop seepage into the water table, although if an aquitard is fractured and contaminated then it can become a long-term source of groundwater contamination due to its low permeability and high HRT.
Tom Kempinski, playwright and screenwriter Peter Kosminsky (born 21 April 1956); writer, playwright, scriptwriter and screenwriter director and producer; has directed Hollywood movies White Oleander and television films, Warriors, The Government Inspector, The Promise, Wolf Hall and The State; born in London in 1956 to Jewish parents. Hyam Maccoby (Hebrew: חיים מכובי, 1924–2004) was a Jewish-British scholar, dramatist, playwright and author of over fifteen scholarly books, specialising in the study of the Jewish and Christian religious traditions. He was known for his theories of the historical Jesus and the origins of Christianity. Maccoby's play The Disputation has been widely performed, and was broadcast by Channel 4 starring Christopher Lee and Toyah Willcox. Hyam Maccoby's daughter is the anti-Zionist BDS activist, organiser of Jews for Justice for Palestinians and author, Deborah Maccoby, acknowledged for her monograph on Isaac Rosenberg. Patrick Marber, playwright and comedian Laurence Marks (British writer) (born 8 December 1948), producer, scriptwriter, screenwriter and one half of writing duo Marks and Gran (with Maurice Gran). Harold Pinter, Nobel prize-winning playwright; Pinter signed the mission statement of Jews for Justice for Palestinians in 2005 and its full-page advertisement, "What Is Israel Doing? A Call by Jews in Britain", published in The Times on 6 July 2006, and he was a patron of the Palestine Festival of Literature. In April 2008, Pinter signed the statement "We're not celebrating Israel's anniversary".
Sources: en.wikipedia.org
The Shengavit Medical Center (Armenian: Շենգավիթ բժշկական կենտրոն) is a multi-disciplinary therapeutic and diagnostic hospital facilities in Yerevan, Armenia. It is the base of the clinical postgraduate training for Yerevan State Medical University and the Ministry of Health (Armenia). The Center operates the following services: obstetrics, operative and endoscopic gynecology, oncology, reproductology, general and endoscopic surgery, micro- and plastic surgery, vascular surgery, ophthalmology, ENT, anesthesiology and critical care medicine, dentistry, diagnostic center, and a clinical laboratory. There are 65 beds available in the hospital, with an average of 7000 patients served per year.
Polypeptide C-terminal thioesters produced by recombinant DNA techniques can be reacted with an N-terminal Cys containing polypeptide by the same native ligation chemistry to provide very large semi-synthetic proteins. Native chemical ligation of this kind using a recombinant polypeptide segment is known as Expressed Protein Ligation. Similarly, a recombinant protein containing an N-terminal Cys can be reacted with a synthetic polypeptide thioester. Thus, native chemical ligation can be used to introduce chemically synthesized segments into recombinant proteins, regardless of size.
=== Mechanism of elastic recoil === The characterization of disorder is consistent with an entropy-driven mechanism of elastic recoil. It is concluded that conformational disorder is a constitutive feature of elastin structure and function.
== History == Mirtazapine was first synthesized at Organon and published in 1989, was first approved for use in major depressive disorder in the Netherlands in 1994, and was introduced in the United States in 1996 under the brand name Remeron.
Peukert stated "the conquest of the world by a secularized, scientific rationality was so overwhelming, that the switch from religion to science as the main source of a meaning-creating mythology for everyday life took place almost without resistance. The result, however, was that science took upon itself a burden of responsibility that it would soon find a heavy one". Peukert wrote science could not offer spiritual consolation as in a world dominated by science the question of "how can the rationalist, secular ideal of the greatest happiness of the greatest number be vindicated, given that it is rebutted in the case of each individual by illness, suffering and death?", which was impossible to answer. As such, scientists came to be concerned with the body of the individual as a way of determining if that individual should be allowed to pass on his/her genes to the next generation with the criterion being whatever the individual was of "value" or not. In this way, there was a shift from the individual as the center of medical concern to the collective of the volkskörper (the "body" of the entire race).
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.